Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.
BMP-6
BMP/Smad signaling
Hyaluronan hydrogel
Multiple myeloma
Osteogenic differentiation
Journal
Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144
Informations de publication
Date de publication:
15 09 2019
15 09 2019
Historique:
received:
19
03
2019
revised:
08
07
2019
accepted:
10
07
2019
pubmed:
16
7
2019
medline:
29
7
2020
entrez:
15
7
2019
Statut:
ppublish
Résumé
Multiple myeloma is a malignant disease characterized by accumulation of clonal plasma cells in the bone marrow. Uncoupling of bone formation and resorption by myeloma cells leads to osteolytic lesions. These are prone to fracture and represent a possible survival space for myeloma cells under treatment causing disease relapse. Here we report on a novel approach suitable for local treatment of multiple myeloma based on hyaluronic acid (HA) hydrogels mimicking the physical properties of the bone marrow. The HA hydrogels are complexed with heparin to achieve sustained presentation and controlled release of bone morphogenetic protein 6 (BMP-6). Others and we have shown that BMP-6 induces myeloma cell apoptosis and bone formation. Using quartz crystal microbalance and enzyme-linked immunosorbent assay, we measured an initial surface density of 400 ng BMP6/cm
Identifiants
pubmed: 31302300
pii: S1742-7061(19)30498-2
doi: 10.1016/j.actbio.2019.07.018
pii:
doi:
Substances chimiques
BMP6 protein, human
0
Bone Morphogenetic Protein 6
0
Hydrogels
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
258-270Informations de copyright
Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.